| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
MSH2, IHC with Interpretation
Test CodeMDFCPIHC70197 or 70197
CPT Codes
88342
Preferred Specimen
Formalin-fixed, paraffin-embedded tissue in an IHC specimen transport kit
Other Acceptable Specimens
4-micron unstained slides
or
Fixed tissue
or
Tissue in neutral buffered ​formalin
or
Fixed tissue
or
Tissue in neutral buffered ​formalin
Instructions
Pathology report is required
Transport Temperature
Room temperature
Specimen Stability
Room temperature: Preferred
Refrigerated: Acceptable
Frozen: Unaccepable
Refrigerated: Acceptable
Frozen: Unaccepable
Methodology
Immunohistochemical Stain
Setup Schedule
Mon-Sat
Report Available
2-3 days
Reference Range
See Laboratory Report
Clinical Significance
Human mismatch repair protein 2 (MSH2) is involved in the initial recognition of mismatched nucleotides during the post replication mismatch repair process. Therefore, the loss of MSH2 function leads to the accumulation of replication errors, which in turn may be responsible for the multiple mutations required for multistage carcinogenesis. Mutations in mismatch repair genes have been linked to hereditary nonpolyposis colon cancer and to sporadic cancers that exhibit microsatellite instability.
MSH2 is reported to be expressed in the nuclei of cells from a variety of tissues including thyroid, heart, smooth muscle, and the germinal centers of lymphoid follicles. In ileum and colon, MSH2 expression has been reported in the crypts, the cells of which are undergoing rapid renewal. They are responsible for the continuous production of different cells which migrate over 2 to 4 days before being sloughed into the lumen. MSH2 is deficient in a high proportion of patients with microsatellite instability (MSI-H). This finding is associated with the autosomal dominant condition known as Hereditary Non-Polyposis Colon Cancer (HNPCC). The anti-MSH2 antibody is useful in screening patients and families for this condition. Colon cancers that are microsatellite unstable have a better prognosis than their microsatellite stable counterparts.
MSH2 is reported to be expressed in the nuclei of cells from a variety of tissues including thyroid, heart, smooth muscle, and the germinal centers of lymphoid follicles. In ileum and colon, MSH2 expression has been reported in the crypts, the cells of which are undergoing rapid renewal. They are responsible for the continuous production of different cells which migrate over 2 to 4 days before being sloughed into the lumen. MSH2 is deficient in a high proportion of patients with microsatellite instability (MSI-H). This finding is associated with the autosomal dominant condition known as Hereditary Non-Polyposis Colon Cancer (HNPCC). The anti-MSH2 antibody is useful in screening patients and families for this condition. Colon cancers that are microsatellite unstable have a better prognosis than their microsatellite stable counterparts.
Performing Laboratory
AmeriPath, Texas
